|D045169||Severe Acute Respiratory Syndrome NIH||0.04|
|D018352||Coronavirus Infections NIH||0.04|
There is one clinical trial.
The associated use of Ivermectin, aspirin, dexamethasone, and enoxaparin (in different combinations and doses) will reduce the impact of COVID infection 19, the need of admission to the intensive care unit, and mortality.
Description: Considering healing and/or reducing symptoms and severity of initial presentationMeasure: Illness development Time: 7 days
Description: Keeping the patient(s) out of ICU, as they do not need mechanical ventilation and/or special intensive careMeasure: Reduction of need ICU admission Time: 14 days
Description: Preventing patient from dyingMeasure: Reduction of mortality rate Time: 30 days
Description: potential need of reducing or augmenting dosesMeasure: Optimyzing doses of drugs used in the clinical trial Time: 14 days
Description: Outcome of adverse effects to one or more drugs used in the clinical trialMeasure: Adverse effects Time: 14 days
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports